Cargando…
Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis
Progressive obstructive lung disease is a characteristic component of cystic fibrosis (CF). It is the pulmonary manifestations, including obstruction and endobronchial infection, which directly contribute to the premature mortality of patients affected with CF. Due to the devastating effects on the...
Autores principales: | Daddario, Martha K, Hagerman, Jennifer K, Klepser, Michael E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108734/ https://www.ncbi.nlm.nih.gov/pubmed/21694901 http://dx.doi.org/10.2147/IDR.S7838 |
Ejemplares similares
-
Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
por: Elson, Elizabeth Claire, et al.
Publicado: (2019) -
Role of Inhalational Aztreonam Lysine in Lower Airway Infections in Cystic Fibrosis: An Updated Literature Review
por: Zeb, Mehwish, et al.
Publicado: (2022) -
The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
por: Heirali, Alya A., et al.
Publicado: (2017) -
Pseudomonas aeruginosa Susceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation
por: Keating, Claire L., et al.
Publicado: (2021) -
Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review
por: Kirkby, Stephen, et al.
Publicado: (2011)